Benjamin Glicksberg, PhD
img_Benjamin Glicksberg
SENIOR FACULTY | Artificial Intelligence and Human Health
Research Topics
Alzheimer's Disease, Bioinformatics, Biomedical Informatics, Biomedical Sciences, Biostatistics, Cardiovascular, Computational Biology, Computer Simulation, Electrophysiology, Epidemiology, Genetics, Genomics, Imaging, MRI, Magnetic Resonance Imaging
Multi-Disciplinary Training Area
Genetics and Genomic Sciences [GGS], Neuroscience [NEU]

PhD, Icahn School of Medicine at Mount Sinai

Post-doctoral, University of Califnornia, San Francisco

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Glicksberg during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Lucem Health
  • LymeLess, Inc.
  • Scale Medicine, Inc.
  • HeartSciences, Inc.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Lucem Health
  • Qualified Health
  • LymeLess, Inc.
  • Network Bio
  • Artemis AI
  • Character Biosciences
  • Pheiron
  • HeartSciences, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.